ISRAEL PLANS TO DIVEST A SHARE IN ISRAEL AEROSPACE INDUSTRIES AND RAFAEL ADVANCED DEFENSE SYSTEMS THIS YEAR - BLOOMBERG NEWS
Israel's Aerospace Industry: Israel is preparing to sell a stake in its aerospace industries, which includes significant players in the defense sector.
Rafael Advanced Defense Systems: The sale is expected to involve Rafael Advanced Defense Systems, a key company in Israel's defense technology landscape.
Trade with 70% Backtested Accuracy
Analyst Views on RFL
About RFL
About the author
ISRAEL PLANS TO DIVEST A SHARE IN ISRAEL AEROSPACE INDUSTRIES AND RAFAEL ADVANCED DEFENSE SYSTEMS THIS YEAR - BLOOMBERG NEWS
Israel's Aerospace Industry: Israel is preparing to sell a stake in its aerospace industries, which includes significant players in the defense sector.
Rafael Advanced Defense Systems: The sale is expected to involve Rafael Advanced Defense Systems, a key company in Israel's defense technology landscape.
Rafael Holdings Reports Q2 Financial Results
- Earnings Decline: Rafael Holdings reported a GAAP EPS of -$0.13 for Q2, showing improvement from -$0.19 in the same period last year, yet still indicating ongoing financial challenges for the company.
- Widening Net Loss: For the three months ending January 31, 2026, the company recorded a net loss of $6.4 million, compared to a loss of $4.6 million a year ago, reflecting rising operational costs and insufficient revenue.
- Cash Position: As of January 31, 2026, Rafael Holdings had cash and cash equivalents of $37.8 million, indicating some liquidity, but future capital efficiency remains a concern.
- Financial Health Warning: The ongoing losses and cash flow situation may impact the company's future financing capabilities and market confidence, necessitating effective measures to improve financial performance.
Rafael Holdings Reports $9.8M Net Loss in Q1, R&D Expenses Rise to $7.5M
- Financial Performance: As of October 31, 2025, Rafael Holdings reported a net loss of $9.8 million for Q1, translating to a loss of $0.19 per share, which is an increase from last year's $9.0 million and $0.37 per share, reflecting the impact of consolidating Cyclo Therapeutics' expenses post-acquisition.
- Surge in R&D Expenses: Research and development expenses soared to $7.5 million this quarter, compared to $1.3 million in the same period last year, primarily due to the inclusion of Cyclo's costs, indicating the company's ongoing commitment to drug development.
- Cash Flow Status: As of October 31, 2025, the company had cash and cash equivalents of $45.5 million, down from $52.8 million on July 31, 2025, highlighting liquidity pressures amid ongoing losses.
- Clinical Trial Progress: Rafael Holdings' Trappsol®Cyclo™ received a recommendation to continue from the Data Monitoring Committee in its pivotal Phase 3 trial for Niemann-Pick Disease Type C1, suggesting the drug could become a significant new treatment option for this rare and fatal genetic disorder.
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data
Continuation of Phase 3 Study: Rafael Holdings' subsidiary, Cyclo Therapeutics, will continue its pivotal phase 3 TransportNPC study for Trappsol® Cyclo™ in treating Niemann-Pick Disease Type C1 (NPC1) after a positive interim analysis by an independent Data Monitoring Committee (DMC).
Trappsol® Cyclo™ Overview: Trappsol® Cyclo™, administered intravenously, aims to address the root cause of NPC1 by mobilizing cholesterol from cells, and has shown a favorable safety profile consistent with earlier studies.
Thursday Sector Leaders: Precious Metals, Real Estate Stocks
Real Estate Sector Performance: Real estate shares have shown relative strength, increasing by approximately 1% overall, with Rafael Holdings rising by about 10.7% and Jones Lang LaSalle up by around 2.3% on Thursday.
Market Commentary Disclaimer: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering
Rights Offering Results: Rafael Holdings, Inc. successfully closed a $25 million rights offering, resulting in subscriptions for 3,130,480 shares of Class B common stock, generating gross proceeds of approximately $4 million. CEO Howard Jonas and affiliates will purchase unsubscribed shares through a backstop private placement totaling about $21 million.
Use of Proceeds: The funds raised from the rights offering and backstop private placement are intended to support regulatory approval efforts and potential launch of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1, pending positive results from ongoing clinical trials.
ISRAEL PLANS TO DIVEST A SHARE IN ISRAEL AEROSPACE INDUSTRIES AND RAFAEL ADVANCED DEFENSE SYSTEMS THIS YEAR - BLOOMBERG NEWS
Israel's Aerospace Industry: Israel is preparing to sell a stake in its aerospace industries, which includes significant players in the defense sector.
Rafael Advanced Defense Systems: The sale is expected to involve Rafael Advanced Defense Systems, a key company in Israel's defense technology landscape.
Rafael Holdings Reports Q2 Financial Results
- Earnings Decline: Rafael Holdings reported a GAAP EPS of -$0.13 for Q2, showing improvement from -$0.19 in the same period last year, yet still indicating ongoing financial challenges for the company.
- Widening Net Loss: For the three months ending January 31, 2026, the company recorded a net loss of $6.4 million, compared to a loss of $4.6 million a year ago, reflecting rising operational costs and insufficient revenue.
- Cash Position: As of January 31, 2026, Rafael Holdings had cash and cash equivalents of $37.8 million, indicating some liquidity, but future capital efficiency remains a concern.
- Financial Health Warning: The ongoing losses and cash flow situation may impact the company's future financing capabilities and market confidence, necessitating effective measures to improve financial performance.
Rafael Holdings Reports $9.8M Net Loss in Q1, R&D Expenses Rise to $7.5M
- Financial Performance: As of October 31, 2025, Rafael Holdings reported a net loss of $9.8 million for Q1, translating to a loss of $0.19 per share, which is an increase from last year's $9.0 million and $0.37 per share, reflecting the impact of consolidating Cyclo Therapeutics' expenses post-acquisition.
- Surge in R&D Expenses: Research and development expenses soared to $7.5 million this quarter, compared to $1.3 million in the same period last year, primarily due to the inclusion of Cyclo's costs, indicating the company's ongoing commitment to drug development.
- Cash Flow Status: As of October 31, 2025, the company had cash and cash equivalents of $45.5 million, down from $52.8 million on July 31, 2025, highlighting liquidity pressures amid ongoing losses.
- Clinical Trial Progress: Rafael Holdings' Trappsol®Cyclo™ received a recommendation to continue from the Data Monitoring Committee in its pivotal Phase 3 trial for Niemann-Pick Disease Type C1, suggesting the drug could become a significant new treatment option for this rare and fatal genetic disorder.
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data
Continuation of Phase 3 Study: Rafael Holdings' subsidiary, Cyclo Therapeutics, will continue its pivotal phase 3 TransportNPC study for Trappsol® Cyclo™ in treating Niemann-Pick Disease Type C1 (NPC1) after a positive interim analysis by an independent Data Monitoring Committee (DMC).
Trappsol® Cyclo™ Overview: Trappsol® Cyclo™, administered intravenously, aims to address the root cause of NPC1 by mobilizing cholesterol from cells, and has shown a favorable safety profile consistent with earlier studies.
Thursday Sector Leaders: Precious Metals, Real Estate Stocks
Real Estate Sector Performance: Real estate shares have shown relative strength, increasing by approximately 1% overall, with Rafael Holdings rising by about 10.7% and Jones Lang LaSalle up by around 2.3% on Thursday.
Market Commentary Disclaimer: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering
Rights Offering Results: Rafael Holdings, Inc. successfully closed a $25 million rights offering, resulting in subscriptions for 3,130,480 shares of Class B common stock, generating gross proceeds of approximately $4 million. CEO Howard Jonas and affiliates will purchase unsubscribed shares through a backstop private placement totaling about $21 million.
Use of Proceeds: The funds raised from the rights offering and backstop private placement are intended to support regulatory approval efforts and potential launch of Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C1, pending positive results from ongoing clinical trials.
